TipRanks
55% OFF
PC:NOR12

NorthLinks Bio

Clinical-stage biotechnology company developing broad-spectrum antiviral preventive medicines for respiratory viral infections. NorthLinks Bio is advancing its lead intranasal candidate HEX17 toward Phase 2b readiness and maintains research operations in St Andrews, Scotland following a reorganization from Pneumagen Ltd.

Leadership & Board

Latest Estimated Valuation

Estimated Valuation
―
Total Amount Raised
$34M
Total Funding Rounds
1
Latest Funding Amount
$34M
Latest Funding Round
Investment
Post-Money Valuation
―

Funding Round

Funding DateFunding RoundAmount RaisedPost-Money Valuation
Jun 23, 2026Investment$34.00M―

Investors

Investor NameFunding Round
RA Capital ManagementInvestment

Similar Companies

A snapshot of private companies similar to NorthLinks Bio, helping you discover and navigate related company profiles.

Related News and Analysis